Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$44.03 USD
-0.16 (-0.36%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $44.02 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Earnings News For RYTM
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
-
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
-
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
-
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
-
Rhythm Pharmaceuticals, Inc. (RYTM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
-
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
-
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
-
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
-
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
-
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
-
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates
-
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
-
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Lags Revenue Estimates
-
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
-
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?
-
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
-
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates